Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA 12,000
-160 (-1.32%)
Oct 5, 2026, 5:28 PM IDT
TLV:TEVA Ratios and Metrics
Market cap in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 141,244 | 104,642 | 76,452 | 34,799 | 34,914 | 29,675 | |
Market Cap Growth | 83.28% | 36.87% | 119.70% | -0.33% | 17.65% | -10.40% |
Enterprise Value | 181,718 | 152,118 | 135,730 | 101,894 | 105,753 | 101,554 |
Last Close Price | 120.00 | 100.90 | 81.01 | 38.15 | 32.99 | 26.95 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 67.16 | 23.28 | - | - | - | 22.88 |
PS Ratio | 2.74 | 1.90 | 1.27 | 0.61 | 0.67 | 0.60 |
PB Ratio | 6.11 | 4.15 | 3.67 | 1.19 | 1.16 | 0.85 |
P/FCF Ratio | 35.20 | 28.59 | 28.02 | 11.48 | 9.53 | 40.43 |
P/OCF Ratio | 24.98 | 19.91 | 16.83 | 7.06 | 6.25 | 11.96 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.43 | 2.77 | 2.25 | 1.79 | 2.02 | 2.06 |
EV/EBITDA Ratio | 13.47 | 9.63 | 8.41 | 6.52 | 7.58 | 7.41 |
EV/EBIT Ratio | 18.06 | 12.07 | 11.05 | 8.88 | 11.30 | 10.60 |
EV/FCF Ratio | 45.28 | 41.56 | 49.75 | 33.60 | 28.86 | 138.35 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 2.18 | 2.18 | 3.18 | 2.50 | 2.52 | 2.10 |
Debt / EBITDA Ratio | 3.84 | 3.39 | 3.98 | 4.53 | 5.26 | 5.19 |
Debt / FCF Ratio | 12.54 | 15.01 | 24.28 | 24.08 | 20.80 | 99.97 |
Net Debt / Equity Ratio | 1.71 | 1.73 | 2.60 | 2.10 | 2.19 | 1.91 |
Net Debt / EBITDA Ratio | 3.10 | 2.76 | 3.36 | 3.93 | 4.75 | 4.86 |
Net Debt / FCF Ratio | 9.83 | 11.91 | 19.87 | 20.25 | 18.11 | 90.80 |
Asset Turnover | 0.43 | 0.43 | 0.40 | 0.36 | 0.33 | 0.32 |
Inventory Turnover | 2.45 | 2.69 | 2.41 | 2.09 | 2.08 | 2.02 |
Quick Ratio | 0.46 | 0.54 | 0.50 | 0.54 | 0.57 | 0.61 |
Current Ratio | 0.88 | 1.04 | 0.98 | 1.02 | 1.05 | 1.14 |
Return on Equity (ROE) | 9.69% | 20.79% | -28.30% | -7.36% | -25.19% | 4.09% |
Return on Assets (ROA) | 5.13% | 6.17% | 5.09% | 4.55% | 3.63% | 3.91% |
Return on Invested Capital (ROIC) | 15.21% | 18.73% | 14.74% | 12.10% | 8.85% | 6.18% |
Return on Capital Employed (ROCE) | 13.50% | 14.50% | 12.70% | 10.20% | 8.20% | 8.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.49% | 4.30% | -7.81% | -5.79% | -24.63% | 4.37% |
FCF Yield | 2.84% | 3.50% | 3.57% | 8.71% | 10.49% | 2.47% |
Buyback Yield / Dilution | -2.24% | -2.83% | -1.07% | -0.81% | -0.27% | -1.10% |
Total Shareholder Return | -2.24% | -2.83% | -1.07% | -0.81% | -0.27% | -1.10% |